

Errata
to the
BRIEFING BOOK
ONCOLOGY DRUG
ADVISORY COMMITTEE MEETING

February 10, 2010


NDA 22-374
OMAPRO™
(omacetaxine mepesuccinate)

ChemGenex Pharmaceuticals, Inc.
3715 Haven Avenue, Suite 100
Menlo Park, CA 94025

Page 38, Figure 1
Symbols in Figure 1 corrected

AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION

Figure 1. Graphical Display of CHR and MCyR Responses in CML-CP Patients



Patients 023/003, 021/004, and 022/003 discontinued the study to receive a HSCT.